Document is current
Any future updates will be listed below
-
Authors
Georgiou, Alexandros https://orcid.org/0000-0001-7500-9251
Stewart, Adam
Vlachogiannis, Georgios https://orcid.org/0000-0003-3114-8772
Pickard, Lisa
Valeri, Nicola https://orcid.org/0000-0002-5426-5683
Cunningham, David https://orcid.org/0000-0001-5158-1069
Whittaker, Steven R. https://orcid.org/0000-0001-9062-7947
Banerji, Udai https://orcid.org/0000-0003-1503-3123
-
Funding
Funding for this research was provided by:
Cancer Research UK
- License Information
-
More Information
Article History
Accepted: 27 July 2021
First Online: 30 August 2021
Declarations
:
: A.G., A.S., G.V., L.P. and S.W. declare no conflicts of interest. D.C. has received grants from 4SC, Amgen, AstraZeneca, Bayer, Celgene, Clovis, Eli Lilly, Janssen, Medimmune, Merck, Merrimack and Sanofi outside the submitted work. N.V. received honoraria and/or travel accommodation from Merck Serono, Pfizer, Bayer, Eli-Lilly and Menarini Silicon Biosystems and U.B. has received honoraria from Astellas, Novartis, Karus Therapeutics, Phoenix Solutions, Eli Lilly, Astex, Vernalis, Janssen and Boehringer Ingelheim. His institutional financial interests include funding for Phase I investigator-initiated trials from Onyx Pharmaceuticals, BTG International, Carrick Therapeutics, Chugai, AstraZeneca and Verastem. He is an employee of the Institute of Cancer Research, London, which is involved in the development of PI3K, HSP90, HDAC, AKT, ROCK, RAF, CHK1 and HSF1 inhibitors.
: The study was carried out in accordance with the declaration of Helsinki and approved by a human research ethics committee.
: All patients provided written informed consent prior to their participation.
